Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

Presentation THT 2023

Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

Presenter: John Teerlink

March 20, 2023

June 2022: Abortion Access, Catching COVID, Climate Cardiology, and More

Podcast Heart Sounds

June 2022: Abortion Access, Catching COVID, Climate Cardiology, and More

June 29, 2022

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

News Features

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

Yael L. Maxwell

June 16, 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

May 22, 2022

Omecamtiv Mecarbil--Is It More Effective in Low EFs and Is It Better Than Digoxin?

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

The GALACTIC-HF Trial

Podcast TCTMD Talking Points

The GALACTIC-HF Trial

April 07, 2021

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

September 16, 2019

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

News Daily News

RELAX-AHF-2: Lack of Benefit With Serelaxin in Acute HF Still a Puzzle for Investigators

August 21, 2019

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.